C. Chi

发表

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Ian M Thompson, J. Crowley, I. Thompson, 2005, JAMA.

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Ziding Feng, Ian M Thompson, I. Thompson, 2006, Journal of the National Cancer Institute.

Male breast cancer after finasteride therapy for benign prostate hyperplasia

Y. Lo, C. Chi, Jui-Ming Liu, 2013 .

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

I. Thompson, P. Goodman, C. Tangen, 2006, Journal of the National Cancer Institute.

Integrative Analysis of four miRNA prognostic signatures of prostate cancer

L. Yao, Min Li, C. Chi, 2020 .

470: Comparison of the Operating Characteristics of PSA for Prostate Cancer Detection for Finasteride and Placebo in the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2006 .

Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase

Ruth Etzioni, I. Thompson, P. Goodman, 2006, Cancer.

Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, S. Lippman, 2006, Cancer Epidemiology Biomarkers & Prevention.

The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.

I. Thompson, P. Goodman, C. Tangen, 2008, The Journal of urology.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

I. Thompson, P. Goodman, C. Tangen, 2007, Journal of Clinical Oncology.